



Drug Coverage Policy

Effective Date 8/1/2024

Coverage Policy Number IP0042

Policy Title Fintepla

Antiseizure Medications – Fintepla

- Fintepla® (fenfluramine oral solution – Zogenix)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Cigna Healthcare Coverage Policies

Fintepla, a serotonin 5-hydroxytryptamine subtype 2 (5-HT₂) agonist, is indicated in patients ≥ 2 years of age for the treatment of **seizures associated with:**

- **Dravet syndrome.**
- **Lennox-Gastaut syndrome.**

Disease Overview

Dravet syndrome is a rare genetic epileptic encephalopathy (dysfunction of the brain) marked with frequent and/or prolonged seizures.^{2,3} It is estimated that 1 out of 15,700 infants born in the US are affected with Dravet syndrome. The seizures generally begin in the first year of life in an otherwise healthy infant. Affected individuals can develop many seizure types: myoclonic, tonic-clonic, absence, atypical absence, atonic, focal aware or impaired awareness (previously called partial seizures), and status epilepticus.³ As the seizures continue, most of the children develop

some level of developmental disability and other conditions associated with the syndrome. Two or more antiseizure medications (ASMs) are often needed to control the seizures; most of the seizures are refractory to medications. The goals of treatment are cessation of prolonged convulsions, reductions in overall seizure frequency, and minimization of treatment side effects.^{4,5} Some patients respond to the ketogenic diet and/or vagus nerve stimulation.

Lennox-Gastaut syndrome, a severe epileptic and developmental encephalopathy, is associated with a high rate of morbidity and mortality.^{6,7} Lennox-Gastaut syndrome most often begins between 3 and 5 years of age.⁶⁻⁹ Affected children experience several different types of seizures, most commonly atonic seizures (sudden loss of muscle tone and limpness) and tonic seizures.^{6,9} The three main forms of treatment of Lennox-Gastaut syndrome are ASMs, dietary therapy (typically the ketogenic diet), and device/surgery (e.g., vagus nerve stimulation, corpus callostomy).⁹ None of the therapies are effective in all cases of Lennox-Gastaut syndrome and the disorder has proven particularly resistant to most therapeutic options.

Guidelines

Fintepla is not mentioned in the current treatment recommendations.

Dravet Syndrome

At this time, there are three drugs approved for the treatment of seizures associated with Dravet syndrome: Diacomit® (stiripentol capsules, powder for oral suspension), Epidiolex® (cannabidiol oral solution), and Fintepla.^{1,10} An expert panel considers valproic acid to be the first-line treatment for Dravet syndrome.⁴ Clobazam, Diacomit, and Fintepla can be considered as either first- or second-line ASMs. Cannabidiol was supported either as first- or second-line treatment. There was modest consensus among caregivers, but no consensus among physicians to support topiramate as first-, second-, or third-line therapy. The Dravet Foundation states that Diacomit, Epidiolex, and Fintepla are considered first-line agents for the treatment of Dravet syndrome.² If control is still inadequate, other therapies to consider are clonazepam, levetiracetam, and zonisamide.^{2,4} Sodium channel blockers (e.g., carbamazepine, oxcarbazepine, lamotrigine, and phenytoin) can worsen seizures in Dravet syndrome. Additionally, vigabatrin and tiagabine may increase the frequency of myoclonic seizures and should be avoided.

Lennox-Gastaut Syndrome

Currently, the FDA-approved drugs for this condition are Fintepla, clobazam, clonazepam, rufinamide, Epidiolex, felbamate, lamotrigine, and topiramate. Despite the lack of level I or level II evidence, valproic acid remains a mainstay in treatment.^{8,9,12} If valproic acid does not provide adequate seizure control, which is almost always the case, lamotrigine should be added as the first adjunctive therapy.⁷ If the combination regimen of valproic acid and lamotrigine does not provide adequate control, then rufinamide should be initiated and either valproic acid or lamotrigine should be discontinued. If seizure control is still not achieved, the next adjunctive therapies to consider are topiramate, clobazam, and felbamate. There is limited evidence for the use of levetiracetam, zonisamide, and Fycompa® (perampanel tablet, oral suspension). Where possible, no more than two ASMs should be used concomitantly; use of multiple ASMs raise the risk of side effects and/or drug-drug interactions.

Medical Necessity Criteria

Fintepla is considered medically necessary when ONE of the following are met:

FDA-Approved Indications

- 1. Dravet Syndrome.** Approve if the patient meets ONE the following (A or B):
 - A) Initial Therapy.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):

- i. Patient is ≥ 2 years of age; AND
 - ii. Patient meets ONE of the following (a or b):
 - a) Patient has tried or is concomitantly receiving at least two other antiseizure medications; OR
Note: Examples of other antiseizure medications include valproic acid, topiramate, clonazepam, levetiracetam, zonisamide.
 - b) Patient has tried or is concomitantly receiving one of clobazam, Epidiolex or Diacomit; AND
 - iii. Fintepla is prescribed by or consultation with a neurologist; OR
- B) Patient is Currently Receiving Fintepla.** Approve for 1 year if the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

- 2. Lennox-Gastaut Syndrome.** Approve if the patient meets ONE of the following (A or B):
- A) Initial Therapy. Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
 - i. Patient is ≥ 2 years of age; AND
 - ii. Patient has tried or is concomitantly receiving at least two other antiseizure medications; AND
Note: Examples of other antiseizure medications include clobazam, Epidiolex, felbamate, lamotrigine, rufinamide, topiramate, valproic acid, levetiracetam, zonisamide, Fycompa, vigabatrin.
 - iii. The medication is prescribed by or in consultation with a neurologist.
 - B) Patient is Currently Receiving Fintepla. Approve for 1 year if the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Note: Receipt of sample product does not satisfy any criteria requirements for coverage.

Conditions Not Covered

Any other use is considered experimental, investigational, or unproven (criteria will be updated as new published data are available).

References

1. Fintepla® oral solution [prescribing information]. Emeryville, CA: Zogenix; December 2023.
2. Dravet Foundation – Dravet Syndrome. Available at: <https://www.dravetfoundation.org/what-is-dravet-syndrome/>. Accessed on April 15, 2024.
3. Shafer PO. Epilepsy Foundation – Dravet Syndrome. Updated August 2020. Available at: <http://www.epilepsy.com/learn/types-epilepsy-syndromes/dravet-syndrome>. Accessed on April 15, 2024.
4. Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. *Epilepsia*. 2022;63(7):1761-1777.
5. Knupp KG1, Wirrell EC. Treatment Strategies for Dravet Syndrome. *CNS Drugs*. 2018;32(4):335-350.

6. Sirven JI, Shafer PO. Epilepsy Foundation – Lennox-Gastaut Syndrome. Updated February 2020. Available at: <https://www.epilepsy.com/learn/types-epilepsy-syndromes/lennox-gastaut-syndrome-lgs>. Accessed on April 15, 2024.
7. Cross JH, Auvin S, Falip M, et al. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. *Front Neurol.* 2017;8:505.
8. Ostendorf AP, Ng YT. Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges, and future directions. *Neuropsych Dis Treatment.* 2017;13:1131-1140.
9. Wheless JW. National Organization for Rare Diseases (NORD) – Lennox-Gastaut syndrome. Updated June 5, 2020. Available at: <https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/#standard-therapies>. Accessed on April 15, 2024.
10. Diacomit® capsules, powder for oral suspension [prescribing information]. Redwood City, CA: Biondex; July 2022.
11. Lennox-Gastaut Syndrome Foundation – Lennox-Gastaut Syndrome. Updated March 1, 2024. Available at: <https://www.lgsfoundation.org/about-lgs-2/what-is-lennox-gastaut-syndrome/>. Accessed on April 15, 2024.
12. Wheless JW. Lennox-Gastaut syndrome. Updated June 5, 2020. Available at: <https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/>. Accessed on April 15, 2024.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Review	<p>Dravet Syndrome, Lennox-Gastaut Syndrome. Updated terminology used for alternative therapy requirement Added 'Patient is Currently Receiving Fintepla' criteria</p> <p>Title change from Fenfluramine.</p>	8/1/2024

The policy effective date is in force until updated or retired.

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.